1. Longitudinal Follow-Up of Blood Telomere Length in HIV-Exposed Uninfected Children Having Received One Year of Lopinavir/Ritonavir or Lamivudine as Prophylaxis
- Author
-
Monnin, Audrey, Vizeneux, Amélie, Nagot, Nicolas, Eymard-Duvernay, Sabrina, Meda, Nicolas, Singata-Madliki, Mandisa, Ndeezi, Grace, Tumwine, James K, Kankasa, Chipepo, Goga, Ameena, Tylleskär, Thorkild, Van de Perre, Philippe, Molès, Jean-Pierre, Salvy-Córdoba, Nathalie, Etablissement Français du Sang [Occitanie] (EFS Occitanie), Université des Antilles (UA), Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université des Antilles (UA)-Etablissement français du don du sang [Montpellier], Centre Muraz [Bobo-Dioulasso, Burkina Faso], University of Fort Hare, Makerere University [Kampala, Ouganda] (MAK), Kabale University School of medicine (KABSOM), University of Zambia [Lusaka] (UNZA), Centers for Disease Control and Prevention [Pretoria, South Africa] (CDC-South Africa), Centers for Disease Control and Prevention (CDC), and University of Bergen (UiB)
- Subjects
[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics ,growth ,virus diseases ,HIV ,mitochondrial DNA ,[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics ,Pediatrics ,Article ,RJ1-570 ,[SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,children ,telomere shortening ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,neuropsychological development ,[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Africa ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,prophylaxis ,Prophylaxis HIV - Abstract
Telomere shortening can be enhanced upon human immunodeficiency virus (HIV) infection and by antiretroviral (ARV) exposures. The aim of this study was to evaluate the acute and long-term effect on telomere shortening of two ARV prophylaxes, lopinavir/ritonavir (LPV/r) and lamivudine (3TC), administered to children who are HIV-exposed uninfected (CHEU) to prevent HIV acquisition through breastfeeding during the first year of life, and to investigate the relationship between telomere shortening and health outcomes at six years of age. We included 198 CHEU and measured telomere length at seven days of life, at week-50 and at six years (year-6) using quantitative polymerase chain reaction. At week-50, telomere shortening was observed among 44.3% of CHEU, irrespective of the prophylactic treatment. Furthermore, this telomere shortening was neither associated with poor growth indicators nor neuropsychological outcomes at year-6, except for motor abilities (MABC test n = 127, β = −3.61, 95%CI: −7.08, −0.14, p = 0.04). Safety data on telomere shortening for infant HIV prophylaxis are scarce. Its association with reduced motor abilities deserves further attention among CHEU but also HIV-infected children receiving ARV treatment.
- Published
- 2021
- Full Text
- View/download PDF